Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 135)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
2 |
|
Bevacizumab |
Approved, Investigational |
Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
3 |
|
Rucaparib |
Approved, Investigational |
Phase 3 |
|
283173-50-2 |
9931954 |
Synonyms:
AG014699
AG-014699
AG-014699|AG014699|AG14447|PF-01367338|Rubraca®
AG14447
AG-14447
|
AG-14447ag-014699Rucaparib
PF-01367338
Rubraca
RUCAPARIB
Rucaparibum
|
|
4 |
|
Topotecan |
Approved, Investigational |
Phase 2, Phase 3 |
|
123948-87-8, 119413-54-6 |
60699 60700 |
Synonyms:
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(Dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
Hycamptamine
HYCAMPTIN
Hycamtamine
Hycamtin
Hydrochloride, nogitecan
Hydrochloride, topotecan
Nogitecan hydrochloride
NSC-609699
Potactasol
SK And F 104864 a
SK And F104864a
SK And F-104864-a
|
SK&F-S-104864A
SKF-104864
SK-S-104864-A
SmithKline beecham brand OF topotecan hydrochloride
Topotecan
TOPOTECAN HCL
Topotecan hydrochloride
Topotecan lactone
Topotecan monohydrochloride, (S)-isomer
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
|
|
5 |
|
Olaparib |
Approved |
Phase 3 |
|
763113-22-0 |
23725625 |
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
6 |
|
Doxorubicin |
Approved, Investigational |
Phase 2, Phase 3 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
7 |
|
Gemcitabine |
Approved |
Phase 3 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
8 |
|
Docetaxel |
Approved, Investigational |
Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
9 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
10 |
|
Atezolizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
11 |
|
Metformin |
Approved |
Phase 2, Phase 3 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
12 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
13 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
14 |
|
Niraparib |
Approved, Investigational |
Phase 3 |
|
1038915-60-4 |
24958200 |
Synonyms:
COMPOUND 56 [PMID 19873981]
compound 56 [PMID 19873981]|MK 4827|MK-4827|Zejula®
JNJ-64091742
MK 4827
|
MK4827
MK-4827
NIRAPARIB
ZL-2306
|
|
15 |
|
Glutamic acid |
Approved, Nutraceutical |
Phase 3 |
|
56-86-0 |
33032 |
Synonyms:
(+)-Estrone
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-beta-D-Glucopyranosyl-beta-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(2R)-2,3-Dihydroxypropanoic acid
(2S)-2-Aminopentanedioate
(2S)-2-Aminopentanedioic acid
(3R,4S,5R)-5-[(1R)-1-Carboxy-2,2-difluoro-1-(phosphonooxy)ethoxy]-4-hydroxy-3-(phosphonooxy)cyclohex-1-ene-1-carboxylate
(R)-2,3-Dihydroxypropanoic acid
(R)-Glycerate
(R)-Glyceric acid
(S)-(+)-Glutamate
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioate
(S)-2-Aminopentanedioic acid
(S)-Glutamate
(S)-Glutamic acid
1,3,5(10)-Estratrien-3-ol-17-one
1-Amino-2-hydroxyethane
1-Aminopropane-1,3-dicarboxylate
1-Amino-propane-1,3-dicarboxylate
1-Aminopropane-1,3-dicarboxylic acid
1-Amino-propane-1,3-dicarboxylic acid
2 Acetamido 2 deoxy D glucose
2 Acetamido 2 deoxyglucose
2 Aminoethanol
2-Acetamido-2-deoxy-D-glucose
2-Acetamido-2-deoxyglucose
2-Amino-1-ethanol
2-Aminoethan-1-ol
2-Aminoethanol
2-Amino-ethanol
2-Aminoethyl alcohol
2-Aminoglutarate
2-Aminoglutaric acid
2-Aminopentanedioate
2-Aminopentanedioic acid
2-Ethanolamine
2-Hydroxyethanamine
2-Hydroxyethylamine
3a,7a,12a-Trihydroxy-5b-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid-24-glycine
3alpha,7alpha,12alpha-Trihydroxy-N-(carboxymethyl)-5beta-cholan-24-amide
3-Hydroxy-1,3,5(10)-estratrien-17-one
3-Hydroxy-17-keto-estra-1,3,5-triene
3-Hydroxyestra-1,3,5(10)-trien-17-one
3-Hydroxyestra-1,3,5(10)-triene-17-one
3-Hydroxyoestra-1,3,5(10)-trien-17-one
3Α,7α,12α-trihydroxy-5β-cholan-24-oylglycine
3Α,7α,12α-trihydroxy-5β-cholanic acid-24-glycine
3Α,7α,12α-trihydroxy-N-(carboxymethyl)-5β-cholan-24-amide
a,b-Hydroxypropionate
a,b-Hydroxypropionic acid
a-Aminoglutarate
a-Aminoglutaric acid
Acetylglucosamine
Acide glutamique
Acido glutamico
ácido glutámico
Acidum glutamicum
Aciglut
Aethanolamin
a-Glutamate
a-Glutamic acid
alpha,beta-Hydroxypropionate
alpha,beta-Hydroxypropionic acid
alpha-Aminoglutarate
alpha-Aminoglutaric acid
alpha-Glutamate
alpha-Glutamic acid
Aluminum L glutamate
Aluminum L-glutamate
Aminoethanol
Aminoglutarate
Aminoglutaric acid
b-Aminoethanol
b-Aminoethyl alcohol
beta-Aminoethanol
beta-Aminoethyl alcohol
beta-Ethanolamine
beta-Hydroxyethylamine
b-Ethanolamine
b-Hydroxyethylamine
Cholylglycine
Colamine
D Glutamate
D1,3,5(10)-Estratrien-3-ol-17-one
D-2,3-Dihydroxypropanoic acid
D-GlcNAc
D-Glutamate
|
D-Glycerate
D-Glyceric acid
D-GroA
E
E 620
E620
E-620
Envision conditioner PDD 9020
Estrone, (+-)-isomer
Estrone, (8 alpha)-isomer
Estrone, (9 beta)-isomer
Estrovarin
ETA
Ethylolamine
FEMA NO. 3285
Follicular hormone
Folliculin
Glt
Glu
Glusate
Glut
Glutacid
Glutamate
Glutamate, potassium
GLUTAMIC ACID
Glutamic acid, (D)-isomer
Glutamicol
Glutamidex
Glutaminate
Glutaminic acid
Glutaminol
Glutaton
Glycerate
Glycine cholate
Glycinol
Glycocholate
Glycocholate sodium
Glycocholic acid, sodium salt
Glycoreductodehydrocholic acid
Glycylcholate
Glycylcholic acid
Hauck brand OF estrone
Hea
H-Glycinol
Hyrex brand OF estrone
INS NO.620
INS-620
Kestrone
L Glutamate
L Glutamic acid
L-(+)-Glutamate
L-(+)-Glutamic acid
L-a-Aminoglutarate
L-a-Aminoglutaric acid
L-alpha-Aminoglutarate
L-alpha-Aminoglutaric acid
L-Glu
L-Glu|L-glutamate|poly-L-glutamate
L-GLUTAMATE
L-Glutamate, aluminum
L-GLUTAMIC ACID
L-Glutaminate
L-Glutaminic acid
L-Glutaminsaeure
MEA
Monoaethanolamin
MONOETHANOLAMINE
N Acetyl D glucosamine
N-(Carboxymethyl)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-amide
N-(Carboxymethyl)-3α,7α,12α-trihydroxy-5β-cholan-24-amide
N-[(3a,5b,7a,12a)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3alpha,5beta,7alpha,12alpha)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3Α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
N-Acetylchitosamine
N-Acetyl-D-glucosamine
N-Choloylglycine
N-Choloyl-glycine
NSC-143503
Oestrone
Olamine
Potassium glutamate
R-Glycerate
R-Glyceric acid
Unigen
Vortech brand OF estrone
Wehgen
Α,β-hydroxypropionate
Α,β-hydroxypropionic acid
Î’-aminoethanol
Î’-aminoethyl alcohol
Î’-ethanolamine
Î’-hydroxyethylamine
|
|
16 |
|
Cediranib |
Investigational |
Phase 3 |
|
288383-20-0 |
9933475 |
Synonyms:
4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
4-(4-FLUORO-2-METHYLINDOL-5-YLOXY)-6-METHOXY-7-[3-(PYRROLIDIN-1-YL)PROPOXY]QUINAZOLINE
AZD 2171
AZD 2171|AZD2171|ZD 2171
AZD-2171
|
CEDIRANIB
RECENTIN
ZD 2171
ZD-2171
|
|
17 |
|
Maleic acid |
Experimental, Investigational |
Phase 3 |
|
110-16-7, 110-17-8 |
444266 444972 |
Synonyms:
(2E)-2-Butenedioate
(2E)-2-Butenedioic acid
(2E)-But-2-enedioate
(2E)-But-2-enedioic acid
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-But-2-enedioate
(2Z)-But-2-enedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(e)-2-Butenedioate
(e)-2-Butenedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(Z)-Butenedioate
(Z)-Butenedioic acid
2-(e)-Butenedioate
2-(e)-Butenedioic acid
2-Butenedioate
2-Butenedioic acid
Allomaleate
Allomaleic acid
Boletate
Boletic acid
cis-1,2-Ethylenedicarboxylate
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
cis-Butenedioate
cis-Butenedioic acid
e297
FC 33
Fumarate
Fumaric acid
Fumaricum acidum
Fumarsaeure
|
Fumarsäure
Furamag
H2Male
Hydrogen maleate
Kyselina maleinova
Lichenate
Lichenic acid
MAE
Mafusol
Maleate
MALEIC ACID
Maleic acid, ammonium salt
Maleic acid, calcium salt
Maleic acid, dipotassium salt
Maleic acid, disodium salt
Maleic acid, iron salt
Maleic acid, monoammonium salt
Maleic acid, monocopper (2+) salt
Maleic acid, monosodium salt
Maleic acid, neodymium salt
Maleic acid, potassium salt
Maleic acid, sodium salt
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Sodium maleate
Toxilate
Toxilic acid
trans-1,2-Ethylenedicarboxylate
trans-1,2-Ethylenedicarboxylic acid
trans-2-Butenedioate
trans-2-Butenedioic acid
trans-But-2-enedioate
trans-But-2-enedioic acid
trans-Butenedioate
trans-Butenedioic acid
|
|
18 |
|
Paclitaxel poliglumex |
Experimental, Investigational |
Phase 3 |
|
263351-82-2 |
|
Synonyms:
CT-2103
PACLITAXEL POLIGLUMEX
|
|
|
19 |
|
Carotenoids |
|
Phase 3 |
|
|
|
20 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
21 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
22 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
23 |
|
Anti-Bacterial Agents |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
topoisomerase I inhibitors |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
26 |
|
Poly(ADP-ribose) Polymerase Inhibitors |
|
Phase 3 |
|
|
|
27 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
28 |
|
Antibiotics, Antitubercular |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Liposomal doxorubicin |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Protein Kinase Inhibitors |
|
Phase 3 |
|
|
|
31 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
32 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
33 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
34 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
35 |
|
Taxane |
|
Phase 3 |
|
|
108169 |
36 |
|
Hypoglycemic Agents |
|
Phase 2, Phase 3 |
|
|
|
37 |
|
Albumin-Bound Paclitaxel |
|
Phase 3 |
|
|
|
38 |
|
Tin Fluorides |
|
Phase 3 |
|
|
|
39 |
|
Vinblastine |
Approved |
Phase 2 |
|
865-21-4 |
241903 13342 |
Synonyms:
(2a,2'b,3b,4a,5b)-VINCALEUKOBLASTINE
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2Α,2'β,3β,4α,5β)-vincaleukoblastine
[3H]-VINBLASTINE
29060-LE|Velban®|Velbe®|vincaleucoblastin|vincaleukoblastine
Cell pharm brand OF vinblastine sulfate
Cellblastin
EG labo brand OF vinblastine sulfate
Faulding brand OF vinblastine sulfate
Gastrozepin brand OF vinblastine sulfate
Gry brand OF vinblastine sulfate
Hexal brand OF vinblastine sulfate
Lemblastine
Lemery brand OF vinblastine sulfate
Lilly brand OF vinblastine sulfate
Nincaluicolflastine
NSC-47842
Rozevin
|
Sulfate, vinblastine
Velban
Velbe
Vinblastin
Vinblastin hexal
Vinblastina
Vinblastina [Dcit]
Vinblastina lilly
Vinblastine
Vinblastine sulfate
Vinblastinsulfat-gry
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
VLB
|
|
40 |
|
Capecitabine |
Approved, Investigational |
Phase 2 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
41 |
|
Xylometazoline |
Approved, Investigational |
Phase 2 |
|
526-36-3 |
5709 |
Synonyms:
2-(4'-Tert-butyl-2',6'-dimethylphenylmethyl)imidazoline
Amidrin
Balkis
Balminil
Chlorohist-la
Decongest
Espa-rhin
Gelonasal
Idasal
Idril N
Imidin
Nasan
Nasengel al
NasenGel ratiopharm
Nasenspray al
NasenSpray ratiopharm
Nasentropfen al
NasenTropfen ratiopharm
|
Novorin
Otradrops
Otraspray
Otriven
Otrivin
Otrivin mentol
OTRIVINE
Otrivine®|xylomethazoline
OTV391
Rapako
Schnupfen endrine
Snup
Stas
Xylometazoline
Xylometazoline hydrochloride
Xylometazoline monohydrochloride
Xylometazolinum
Xylomethazoline
|
|
42 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
43 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
44 |
|
Nintedanib |
Approved |
Phase 2 |
|
656247-17-5 |
135423438 9809715 |
Synonyms:
BIBF 1120
BIBF1120
BIBF-1120
BIBF-1120|BIBF1120|Ofev®|Vargatef®
INTEDANIB
|
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
NINTEDANIB
Nintedanib esylate
Ofev
Vargatef
|
|
45 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
50-35-1 |
5426 |
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
46 |
|
Iodine |
Approved, Investigational |
Phase 2 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
47 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
48 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 1, Phase 2 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
49 |
|
Anastrozole |
Approved, Investigational |
Phase 2 |
|
120511-73-1 |
2187 |
Synonyms:
2,2'-(5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
a,a,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Anastrazole
Anastrole
Anastrozol
ANASTROZOLE
Arimidex
Arimidex®
Astra brand OF anastrozole
|
AstraZeneca brand OF anastrozole
ICI D1033
ICI-D1033
NASTROSA
ZD1033
ZD-1033
Zeneca brand OF anastrozole
Zeneca ZD 1033
Α,α,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
|
|
50 |
|
Lenvatinib |
Approved, Investigational |
Phase 2 |
|
417716-92-8 |
9823820 |
Synonyms:
4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
e 7080
E 7080|ER-203492-00|Kisplyx®|Lenvima®
e7080
E-7080
|
ER-203492-00
KISPLYX
LENVATINIB
LENVATINIB MESYLATE
Lenvima
UNII-ee083865g2
|
|
Interventional clinical trials:
(show top 50)
(show all 107)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? |
Unknown status |
NCT00719303 |
Phase 3 |
|
2 |
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma |
Unknown status |
NCT00807768 |
Phase 3 |
Carboplatin;Paclitaxel |
3 |
A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma |
Completed |
NCT00951496 |
Phase 3 |
Carboplatin;Cisplatin;Paclitaxel |
4 |
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
Completed |
NCT00262847 |
Phase 3 |
Carboplatin;Paclitaxel |
5 |
A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma |
Completed |
NCT00006011 |
Phase 3 |
Doxorubicin Hydrochloride;Cisplatin;Paclitaxel |
6 |
Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy |
Recruiting |
NCT04575935 |
Phase 3 |
Chemotherapy |
7 |
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients |
Recruiting |
NCT04227522 |
Phase 3 |
Rucaparib;Placebos |
8 |
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) |
Recruiting |
NCT05281471 |
Phase 3 |
Platinum chemotherapy: carboplatin (preferred) or cisplatin;Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin;Bevacizumab (or biosimilar) |
9 |
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) |
Active, not recruiting |
NCT00565851 |
Phase 3 |
Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel |
10 |
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer |
Active, not recruiting |
NCT02839707 |
Phase 2, Phase 3 |
Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride |
11 |
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer |
Active, not recruiting |
NCT03914612 |
Phase 3 |
Carboplatin;Paclitaxel |
12 |
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy |
Active, not recruiting |
NCT00108745 |
Phase 3 |
Paclitaxel;Paclitaxel Poliglumex |
13 |
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
NCT02446600 |
Phase 3 |
Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride |
14 |
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) |
Active, not recruiting |
NCT02502266 |
Phase 2, Phase 3 |
Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride |
15 |
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer |
Active, not recruiting |
NCT02065687 |
Phase 2, Phase 3 |
Carboplatin;Metformin Hydrochloride;Paclitaxel |
16 |
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma |
Active, not recruiting |
NCT00942357 |
Phase 3 |
Carboplatin;Cisplatin;Paclitaxel |
17 |
Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) |
Active, not recruiting |
NCT03422198 |
Phase 3 |
|
18 |
Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel |
Active, not recruiting |
NCT02501954 |
Phase 3 |
Cisplatin;Carboplatin;Paclitaxel |
19 |
A Phase III Randomized, Open Label Study of A Phase III Randomized, Open Label Study of NiraParib Maintenance After Carboplatin and Paclitaxel in optimaLly debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus) |
Not yet recruiting |
NCT05460000 |
Phase 3 |
3 cycles chemotherapy instead of 6 cycles chemotherapy;6 cycles chemotherapy |
20 |
Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study |
Unknown status |
NCT00226798 |
Phase 2 |
Capecitabine (Xeloda) |
21 |
A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA) |
Unknown status |
NCT03405454 |
Phase 2 |
durvalumab;standard chemotherapy |
22 |
A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium |
Unknown status |
NCT02866370 |
Phase 2 |
Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin |
23 |
A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma |
Completed |
NCT01097746 |
Phase 2 |
Carboplatin;Paclitaxel |
24 |
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
Completed |
NCT00888615 |
Phase 2 |
Elesclomol Sodium;Paclitaxel |
25 |
A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum |
Completed |
NCT02315430 |
Phase 2 |
Cabozantinib S-malate |
26 |
A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Completed |
NCT02853318 |
Phase 2 |
Cyclophosphamide |
27 |
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Completed |
NCT02923739 |
Phase 2 |
Paclitaxel |
28 |
A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
Completed |
NCT00820898 |
Phase 2 |
Gemcitabine Hydrochloride |
29 |
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer |
Completed |
NCT01005329 |
Phase 2 |
Carboplatin;Cisplatin;Paclitaxel |
30 |
A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
Completed |
NCT00888173 |
Phase 2 |
Brivanib Alaninate |
31 |
A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
Completed |
NCT01011933 |
Phase 2 |
Selumetinib |
32 |
A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
Completed |
NCT01132820 |
Phase 2 |
Cediranib Maleate |
33 |
A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma |
Completed |
NCT00979992 |
Phase 2 |
Sunitinib Malate |
34 |
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
Completed |
NCT01642082 |
Phase 2 |
|
35 |
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
Completed |
NCT01225887 |
Phase 2 |
Nintedanib |
36 |
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium |
Completed |
NCT01210222 |
Phase 2 |
|
37 |
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer |
Completed |
NCT01307631 |
Phase 2 |
Akt Inhibitor MK2206 |
38 |
Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas |
Completed |
NCT01914510 |
Phase 2 |
ENMD-2076 |
39 |
Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage |
Completed |
NCT00416455 |
Phase 1, Phase 2 |
ferumoxtran-10 |
40 |
A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer |
Completed |
NCT00072176 |
Phase 2 |
temsirolimus |
41 |
A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma |
Completed |
NCT00025467 |
Phase 2 |
thalidomide |
42 |
Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma |
Completed |
NCT01824615 |
Phase 2 |
Sunitinib |
43 |
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab |
Recruiting |
NCT04739800 |
Phase 2 |
Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride |
44 |
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer |
Recruiting |
NCT02364713 |
Phase 2 |
Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride |
45 |
EON: A Single-Arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer |
Recruiting |
NCT05026606 |
Phase 2 |
|
46 |
Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer |
Recruiting |
NCT02068794 |
Phase 1, Phase 2 |
|
47 |
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) |
Recruiting |
NCT03866382 |
Phase 2 |
Cabozantinib S-malate |
48 |
A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer |
Recruiting |
NCT04719273 |
Phase 2 |
Extended-release Onapristone;Anastrozole |
49 |
BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas |
Recruiting |
NCT03355976 |
Phase 2 |
Nivolumab;Ipilimumab |
50 |
A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma |
Recruiting |
NCT05112601 |
Phase 2 |
|
Cochrane evidence based reviews: mesonephroma
|